Prior Authorization Assistance

Initiate prior authorizations (PA) for ENBREL by signing up for ENBREL Prior Auth Assist.

Insurance Help

Initiate prior authorizations (PAs) for ENBREL by signing up for ENBREL Prior Auth Assist.

Go to ENBREL Prior Auth Assist

Simple steps to getting your patients started on ENBREL

Check here for updated insurance forms, brochures, and the most up-to-date resources that will help you work with health insurance companies in obtaining coverage for ENBREL for your patients.

You will need Adobe Acrobat Reader to view certain documents on this page. If you do not already have it, download it for free from Adobe's website.

Get Adobe® Reader®.

Insurance Forms

Sample Letters of Medical Necessity

Below are sample letters of medical necessity that you can customize for your patients:

Uninsured Patients

You may choose to refer uninsured patients to the ENcourage Foundation®—a nonprofit foundation supported by Amgen that has helped more than 32,870 eligible patients receive ENBREL. For more information, visit www.ENcourageFoundation.com1.


 
INDICATIONS

ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone.

ENBREL is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients ages 2 and older.

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

ENBREL is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.

ENBREL is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Supportive data

Moderate to Severe Plaque Psoriasis
In medical studies, nearly half of patients saw 75% skin clearance in their moderate to severe plaque psoriasis in 3 months with ENBREL. Overall, 3 out of 4 patients saw 50% skin clearance in 3 months. ENBREL can work fast; many patients saw improvement within 2 months. Your results may vary.

Psoriatic Arthritis
In a medical study, ENBREL was shown to be effective in about 50% of psoriatic arthritis patients who used it at 6 months. Clinical responses were apparent at the time of the first visit (4 weeks) and were maintained through 6 months of therapy.

The ENBREL Support™ card offers eligible patients help with their out-of-pocket costs.
Injection Demos
Watch short, informative videos designed to help ENBREL patients self-inject in the comfort of their own homes.

Learn more about
administration
options arrow

Lynne was first diagnosed with plaque psoriasis when she was only 9 years old and has tried many different treatments since that time.

Then, Lynne started taking ENBREL to manage her symptoms.

"ENBREL has allowed me to dress however I want now."